Skip to Main Content

Paper Details

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers.
Journal for ImmunoTherapy of Cancer
32
2021
CSC, CSF t-DNA, HR, ICI, LMM, NSCLC, Pembrolizumab, cutaneous squamous carcinoma, hormone-receptor, hormone-receptor (HR)-positive breast carcinoma, leptomeningeal metastases, leptomeningeal metastasis, non-small cell lung cancer, patients, solid tumors, t-DNA, tumor, tumor-derived DNA, tumors
Author NameAffiliation
Kenneth W KinzlerSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Kenneth W KinzlerThe Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University
Kenneth W KinzlerLudwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
Kenneth W KinzlerSol Goldman Pancreatic Cancer Research Center, Johns Hopkins University
Nickolas PapadopoulosSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Nickolas PapadopoulosThe Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University
Nickolas PapadopoulosLudwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
Nickolas PapadopoulosSol Goldman Pancreatic Cancer Research Center, Johns Hopkins University
Chetan BettegowdaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Chetan BettegowdaThe Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University
Chetan BettegowdaJohns Hopkins University
Chetan BettegowdaLudwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
Chetan BettegowdaSol Goldman Pancreatic Cancer Research Center, Johns Hopkins University
  • 1 - 13

Datasets

Release 1.2